Jesus Pina Garza
Neurology with Special Qualifications in Child Neurology · Nashville, TNNPI 1205928611
Payments from drug & device makers
Across 2,315 payments — averaging $621.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$286K
- Eisai Inc.$236K
- SK Life Science, Inc.$197K
- Neurelis, Inc.$146K
- Jazz Pharmaceuticals Inc.$125K
- UCB SA$82K
- plus $366K from 48 others
Across 3 payments — averaging $413.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB, Inc.$1K
What the payments were for
- Consulting fees$231,85116%
- Speaking & faculty fees$1,047,69673%
- Travel & lodging$116,0368%
- Food & beverage$42,1323%
- Education$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fycompa$279,697
- Epidiolex$195,965
- XCOPRI$185,465
- VALTOCO$142,768
- Fintepla$117,160
- Nayzilam$78,103
- APTIOM$48,205
- SYMPAZAN$47,948
- DAYBUE$47,933
- ZTALMY$41,127
- Briviact$28,023
- OXTELLAR XR$23,629
- Vimpat$9,247
- Banzel$7,419
- Cenobamate$6,450
- NONE$3,420
- Keppra$2,808
- ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE$1,000
- QELBREE$342
- VNS - Symmetry$129
How this compares
$1,437,793 in reported general payments places this provider in the 90th percentile of 47 neurology with special qualifications in child neurology providers in Tennessee.
See all neurology with special qualifications in child neurology providers in Tennessee →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 60 | $102,777 |
| BriviactBrivaracetam | 12 | $38,759 |
| EpidiolexCannabidiol (Cbd) | 11 | $36,268 |
| FycompaPerampanel | 23 | $26,812 |
| TopamaxTopiramate | 21 | $19,935 |
| Clobazam | 42 | $3,543 |
| Diazepam | 13 | $872 |
| Oxcarbazepine | 12 | $829 |
| Lacosamide | 12 | $581 |
| Clonazepam | 36 | $403 |
| Topiramate | 17 | $251 |
| Risperidone | 16 | $204 |
| Levetiracetam | 13 | $136 |
| Lamotrigine | 17 | $124 |
| Citalopram HbrCitalopram Hydrobromide | 13 | $80 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $197,078 | $102,77760 claims |
| UCB, Inc.Briviact | $285,503 | $38,75912 claims |
| Eisai Inc.Fycompa | $236,120 | $26,81223 claims |
| Upsher-smith Laboratories LLCTopiramate | $42 | $25117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 47 neurology with special qualifications in child neurology providers in Tennessee.
Other neurology with special qualifications in child neurology in Nashville
- James FryNashville$2.5M
- Jeffrey NeulNashville$885K
- William BurnetteNashville$392K
- Robert CarsonNashville$342K
- Cary FuNashville$218K
- Althea SheltonNashville$167K
- Mariana CiobanuNashville$102K
- Timothy LivingstonNashville$14K
- Ngochanh VuNashville$4K
- Kaitlin JamesNashville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.